A deep analysis of semaglutide’s phase 3 AD trials shows no cognitive or functional benefit despite biomarker gains, yet ...

By Tarun Sai Lomte A small but carefully monitored 20-week study reveals that semaglutide delivers weight loss in older ...

By Deena Beasley and Julie Steenhuysen SAN DIEGO, Dec 3 (Reuters) - Details from two large trials of Novo Nordisk's GLP-1 ...

Oral semaglutide fails to slow clinical progression, but biomarker changes emerge ...

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an ...

There are improved cardiovascular outcomes associated with semaglutide therapy in patients with overweight or obesity without diabetes.

The authors conclude that early use of semaglutide may serve as an effective adjunctive strategy to mitigate the metabolic ...

Oral semaglutide did not significantly reduce disease progression in patients with early Alzheimer disease, according to results from two phase 3 trials.

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

By Deena Beasley SAN DIEGO Dec 2 (Reuters) - Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases.